Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-PSMA-617 + Pembrolizumab in mCRPC
NCT03805594Phase 1Completed
- Sponsor
- University of California, San Francisco
- Start
- May 2019
- Primary completion
- Jan 2024
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label trial of lutetium lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer (mCRPC) (4 arms), sponsored by University of California, San Francisco. Primary endpoints: Dose Limiting Toxicities at 1 year and Objective Response Rate at 2 years. Started May 2019; status: completed.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03805594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03805594.